Activity of single-agent decitabine in atypical chronic myeloid leukemia

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 6, 2016, Pages 790-794

  Hausmann, Heidi ^a   Bhatt, Vijaya R ^a   Yuan, Ji ^a   Maness, Lori J ^a   Ganti, Apar K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Atypical chronic myeloid leukemia; decitabine; hematopoietic stem cell transplant; paraneoplastic vasculitis

Indexed keywords

BUDESONIDE; BUSULFAN; CD34 ANTIGEN; CD45 ANTIGEN; DECITABINE; FLUDARABINE; HEMOGLOBIN; MEPREDNISONE; MICROSOMAL AMINOPEPTIDASE; PREDNISONE; RAPAMYCIN; RHEUMATOID FACTOR; STEM CELL FACTOR RECEPTOR; TACROLIMUS; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; BONE MARROW BIOPSY; CANCER THERAPY; CASE REPORT; CAUCASIAN; COMMON CAROTID ARTERY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EMERGENCY WARD; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HUMAN; LABORATORY TEST; LEUKOCYTOSIS; LUNG EMBOLISM; LYMPHADENOPATHY; MIDDLE AGED; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROMYELOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THORAX PAIN; THROMBOCYTOPENIA; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, INTRAVENOUS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84993949390     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155215605662     Document Type: Article

References (16)

1. Vardiman JW, Bennett JM, Bain BJ, et al.Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Lee Harris N, et al.(eds). WHO classification of tumors of haematopoietic and lymphoid tissues, Lyon: IARC Press, 2008, pp. 80-81.
2. Gotlib J, Maxson JE, George TI, et al. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. Blood 2013; 122: 1707-1711.
3. Breccia M, Biondo F, Latagliata R, et al. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 2006; 91: 1566-1568.
4. Onida F, Ball G, Kantarjian HM, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer 2002; 95: 1673-1684.
5. Kermani TA, Warrington KJ, Amin S,. Malignancy risk in vasculitis. Ther Adv Musculoskelet Dis 2011; 3: 55-63.
6. Fleming S, Hellstrom-Lindberg E, Burbury K, et al. Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome. Leuk Lymphoma 2012; 53: 1613-1616.
7. Park JK, Gelber AC, Zheng G, et al. Large-vessel vasculitis as an early manifestation of chronic myelomonocytic leukemia. J Clin Oncol 2011; 29: e601-e603.
8. Albert DA, Burns CM,. Rheumatologic manifestations in myelodysplastic syndrome. J Clin Rheumatol 2012; 18: 148-150.
9. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19: 2915-2926.
10. Hernandez JM, del Canizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000; 11: 441-444.
11. Saba HI,. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3: 807-817.
12. Tong X, Li J, Zhou Z, et al. Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. Leuk Lymphoma 2015; 56: 1911-1913.
13. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368: 1781-1790.
14. Garcia JL, Font de Mora J, Hernandez JM, et al. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood 2003; 102: 2699-2700.
15. Koldehoff M, Steckel NK, Hegerfeldt Y, et al. Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia. Int J Lab Hematol 2012; 34: e3-e5.
16. Mittal P, Saliba RM, Giralt SA, et al. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant 2004; 33: 1005-1009.